Article

Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

05/10/2022

Customized drug discovery offers integrated target-to-lead and target-to-clinic ready small molecules Excerpt from the Press Release: WILMINGTON, Mass. & BOSTON–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched LogicaTM, an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Valo’s…

Read More

HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA

05/09/2022

Excerpt from the Press Release: PLYMOUTH MEETING, PA, April 27, 2022— Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the initiation of its Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia…

Read More

ChristianaCare Scientists Show for the First Time That Tumor Cells Can Manipulate the Body’s Natural Antibody Response to Triple Negative Breast Cancer

05/09/2022

Findings point to potential new therapeutic targets for this highly aggressive, drug-resistant breast cancer subtype Excerpt from the Press Release: In breakthrough research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, scientists have discovered that a protein secreted by tumor cells can switch off the body’s natural defenses against triple negative breast cancer (TNBC).…

Read More

Preclinical Research Published in Science Advances Demonstrates Repertoire Immune Medicines’ Cell-Tethering Technology Delivers Potent Interleukin-12 Directly to Solid Tumors Potentially Improving Effectiveness of Cellular Immunotherapies

05/09/2022

Repertoire’s proprietary cell-tethering technology limits systemic toxicity typically associated with use of immunomodulatory IL-12 and allows direct delivery to solid tumors in mouse models Tethered IL-12 repolarizes the tumor microenvironment potentially creating improved conditions for cellular immunotherapies to work effectively Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Repertoire Immune Medicines announced today that Science Advances published preclinical research…

Read More

Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Was Associated with Improved Fat and Nutrient Absorption

05/06/2022

Preclinical data published in Journal of Clinical Nutrition highlight potential applications of ALC-078 cartridge in short bowel syndrome nutrition management Excerpt from the Press Release: NEWTON, Mass. , April 27, 2022 /PRNewswire/ — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced publication of preclinical data from the company’s development…

Read More

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

05/06/2022

Based on positive feedback provided by FDA on key clinical design details Jasper plans to initiate registrational studies in AML and MDS patients Excerpt from the Press Release: REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc., (NASDAQ: JSPR) a biotechnology company focused on hematopoietic stem cell therapies, today announced that after…

Read More

Pyrukynd ushers in new era for rare cellular metabolic disease

05/06/2022

The approval of the first oral pill to treat a rare anemia heralds the arrival of a new class of agents that could shake up enzyme replacement therapies for metabolic disease. Excerpt from the Press Release: The US approval in February of Agios Pharmaceuticals’ Pyrukynd (mitapivat) for pyruvate kinase deficiency (PKD) is a first on…

Read More

VITRAC Therapeutics Initiates a Phase 1/2 Clinical Trial with the Aurora Kinase A inhibitor VIC-1911 in GVHD Prophylaxis

05/05/2022

Excerpt from the Press Release: VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1/2 clinical trial of VIC-1911 in combination with sirolimus and post-transplant cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis in myeloablative allogeneic stem cell transplantation. VIC-1911 is an oral selective Aurora kinase A inhibitor (AURKA). The trial is being carried out at the University…

Read More

Virpax Successfully Completes Initial Preclinical Studies for VRP324

05/05/2022

-Nasal CBD Candidate to Manage Seizures Associated with Epilepsy in Children and Adults- Excerpt from the Press Release: Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, CNS disorders and anti-viral indications, reported preclinical pharmacokinetics (PK) results for VRP324 (MET-CBD), a nose-to-brain delivery platform for CBD…

Read More

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

05/05/2022

PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway  Plans underway for…

Read More